Merck Research Laboratories CMO Eliav Barr at #JPM24 (Brian Benton Photography)
Merck stops another Winrevair study early based on positive results from earlier PAH trial
Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form of high blood …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
